SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) April 28, 2004
REGENERON PHARMACEUTICALS, INC.
| NEW YORK | 0-19034 | No. 13-3444607 | ||
|
|
||||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| 777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY | 10591-6707 | |
|
|
||
| (Address of principal executive offices) | (Zip Code) |
| Registrant’s telephone number, including area code | (914) 347-7000 | ||
|
|
NOT APPLICABLE
Page 1 of 3
| INFORMATION TO BE INCLUDED IN REPORT | ||||||||
| Item 5. Other Events and Required FD Disclosure. | ||||||||
| SIGNATURE | ||||||||
INFORMATION TO BE INCLUDED IN REPORT
Item 5. Other Events and Required FD Disclosure.
In conjunction with the purchase of Immunex Corporation by Amgen Inc. in 2002, Amgen was required by the U.S. Federal Trade Commission to dispose of all of its Regeneron common shares. This divestiture was subject to certain quarterly volume limitations unless otherwise agreed to by Regeneron. On April 28, 2004, Regeneron gave its consent to Amgen to enter into a forward contract for the sale of approximately 2.9 million shares, representing Amgen's entire holding of Regeneron common stock.
-2-
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Regeneron Pharmaceuticals, Inc. | ||
|
By: /s/ Murray
A. Goldberg |
||
|
Murray A. Goldberg Senior Vice President, Finance and Administration, Chief Financial Officer, Treasurer & Assistant Secretary |
||
| Date: April 28, 2004 |
-3-